Invokana® is a SGLT2 inhibitor drug indicated for the treatment of type-2 diabetes. In December of 2015, the Food and Drug Administration required a label change on all SGLT2 inhibitors to warn of the risk of ketoacidosis. Ketoacidosis is a potentially fatal side effect where the body overproduces ketones, usually a symptom of insulin deficiency in type-2 diabetics. Symptoms of ketoacidosis may include abdominal pain, nausea, exhaustion, and trouble breathing, often leading to an emergency room visit and hospitalization.
Ketoacidosis risk has been seen in all SGLT2 inhibitors, including Farxiga®, Glyxambi®, Invokamet®, Jardiance®, and Xigduo®. However, these drugs have also been linked to other serious conditions, including kidney failure and heart attack. Litigation against the manufacturers of these drugs is already pending.
If you or a loved one has been prescribed Invokana® or any other SGLT2 inhibitor and were diagnosed with ketoacidosis, kidney failure, or heart attack, you may be entitled to compensation. Our nationally-recognized team of Invokana® attorneys is ready to help. Call The Law Offices of Larry H. Parker today at (800) 333-0000 for a free, no obligation consultation.
